These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38945364)

  • 1. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae.
    Martinez-Guerra BA; Xancal-Salvador LF; Esteban-Kenel V; Tello-Mercado AC; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Ponce-de-Leon A; Gonzalez-Lara MF
    J Glob Antimicrob Resist; 2024 Sep; 38():212-215. PubMed ID: 38945364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG; Bauer MJ; Butkiewicz D; Hinton A; Henderson A; Harris PNA; Paterson DL
    Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gupta A; Malik S; Kaminski M; Landman D; Quale JM
    Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
    Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
    Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
    Medeiros AA; Crellin J
    Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
    Rawat D; Hasan AS; Capoor MR; Sarma S; Nair D; Deb M; Pillai P; Aggarwal P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):131-9. PubMed ID: 19323045
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Grupper M; Stainton SM; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
    Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
    Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Abdelraouf K; Stainton SM; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing
    Stone TJ; Kilic A; Williamson JC; Palavecino EL
    Antibiotics (Basel); 2023 May; 12(6):. PubMed ID: 37370272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
    Al-Tamimi M; Albalawi H; Shalabi M; Abu-Raideh J; Khasawneh AI; Alhaj F
    Ann Clin Microbiol Antimicrob; 2022 May; 21(1):20. PubMed ID: 35599329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
    Thelen H; Dilworth TJ; Mercier RC
    Chemotherapy; 2022; 67(4):261-268. PubMed ID: 36417841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
    Birgy A; Madhi F; Jung C; Levy C; Cointe A; Bidet P; Hobson CA; Bechet S; Sobral E; Vuthien H; Ferroni A; Aberrane S; Cuzon G; Beraud L; Gajdos V; Launay E; Pinquier D; Haas H; Desmarest M; Dommergues MA; Cohen R; Bonacorsi S;
    J Antimicrob Chemother; 2021 Oct; 76(11):2839-2846. PubMed ID: 34453533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.